- Home
- PRCT
as 07-26-2024 4:00pm EST
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.
Upcoming Earnings Alert:
Get ready for potential market movements as PROCEPT BioRobotics Corporation PRCT prepares to release earnings report on 01 Aug 2024.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SAN JOSE |
| Market Cap: | 3.4B | IPO Year: | 2021 |
| Target Price: | $62.60 | AVG Volume (30 days): | 561.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $24.83 - $77.00 | Next Earning Date: | 08-01-2024 |
| Revenue: | $156,326,000 | Revenue Growth: | 83.44% |
| Revenue Growth (this year): | 60.08% | Revenue Growth (next year): | 40.55% |
Stock Insider Trading Activity of PROCEPT BioRobotics Corporation (PRCT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Nouri Alaleh | PRCT | EVP, CLO, CORP. SEC. | Jun 17 '24 | Sell | $62.04 | 8,952 | $555,425.94 | 53,520 | SEC Form 4 |
| Nouri Alaleh | PRCT | EVP, CLO, CORP. SEC. | Jun 17 '24 | Sell | $63.30 | 1,048 | $66,337.98 | 52,472 | SEC Form 4 |
| Shiblaq Hisham | PRCT | EVP, Chief Comm. Officer | Jun 10 '24 | Sell | $68.24 | 26,046 | $1,777,498.85 | 55,860 | SEC Form 4 |
| Nouri Alaleh | PRCT | EVP, CLO, CORP. SEC. | May 3 '24 | Sell | $60.84 | 391 | $23,788.44 | 92,513 | SEC Form 4 |
| Nouri Alaleh | PRCT | EVP, CLO, CORP. SEC. | May 3 '24 | Sell | $61.28 | 1,536 | $94,126.08 | 90,977 | SEC Form 4 |
| Nouri Alaleh | PRCT | EVP, CLO, CORP. SEC. | May 3 '24 | Sell | $62.79 | 13,935 | $874,978.65 | 77,042 | SEC Form 4 |
| Nouri Alaleh | PRCT | EVP, CLO, CORP. SEC. | May 3 '24 | Sell | $63.38 | 14,437 | $915,017.06 | 62,605 | SEC Form 4 |
| Nouri Alaleh | PRCT | EVP, CLO, CORP. SEC. | May 3 '24 | Sell | $64.04 | 133 | $8,517.32 | 62,472 | SEC Form 4 |
| Krummel Thomas M | PRCT | Director | May 1 '24 | Sell | $60.00 | 20,000 | $1,200,000.00 | 45,631 | SEC Form 4 |
| Nouri Alaleh | PRCT | EVP, CLO, CORP. SEC. | Mar 18 '24 | Sell | $48.83 | 441 | $21,534.03 | 62,472 | SEC Form 4 |
| Shiblaq Hisham | PRCT | EVP, Chief Comm. Officer | Mar 18 '24 | Sell | $48.83 | 244 | $11,914.52 | 55,860 | SEC Form 4 |
| Waters Kevin | PRCT | EVP, CFO | Mar 18 '24 | Sell | $48.83 | 1,024 | $50,001.92 | 102,149 | SEC Form 4 |
| Zadno Reza | PRCT | President, CEO | Mar 18 '24 | Sell | $48.83 | 5,391 | $263,242.53 | 241,319 | SEC Form 4 |
| Nouri Alaleh | PRCT | EVP, CLO, CORP. SEC. | Mar 6 '24 | Sell | $46.67 | 2,749 | $128,295.83 | 62,913 | SEC Form 4 |
| Zadno Reza | PRCT | President, CEO | Mar 6 '24 | Sell | $46.67 | 9,179 | $428,383.93 | 246,710 | SEC Form 4 |
| Shiblaq Hisham | PRCT | EVP, Chief Comm. Officer | Mar 6 '24 | Sell | $46.67 | 1,759 | $82,092.53 | 56,104 | SEC Form 4 |
| Waters Kevin | PRCT | EVP, CFO | Mar 6 '24 | Sell | $46.67 | 3,435 | $160,311.45 | 49,416 | SEC Form 4 |
| Krummel Thomas M | PRCT | Director | Mar 4 '24 | Sell | $48.21 | 11,762 | $567,058.96 | 73,869 | SEC Form 4 |
| Krummel Thomas M | PRCT | Director | Mar 4 '24 | Sell | $48.99 | 8,238 | $403,583.74 | 65,631 | SEC Form 4 |
| Waters Kevin | PRCT | EVP, CFO | Feb 12 '24 | Sell | $50.16 | 22,349 | $1,121,061.60 | 33,523 | SEC Form 4 |
| Nouri Alaleh | PRCT | EVP, CLO, CORP. SEC. | Feb 7 '24 | Sell | $49.95 | 5,306 | $265,053.27 | 47,351 | SEC Form 4 |
| Nouri Alaleh | PRCT | EVP, CLO, CORP. SEC. | Feb 7 '24 | Sell | $49.97 | 14,694 | $734,313.55 | 47,351 | SEC Form 4 |
| Waters Kevin | PRCT | EVP, CFO | Feb 7 '24 | Sell | $50.00 | 904 | $45,200.00 | 33,523 | SEC Form 4 |
| Waters Kevin | PRCT | EVP, CFO | Feb 7 '24 | Sell | $50.09 | 28,677 | $1,436,379.31 | 33,523 | SEC Form 4 |
| Nouri Alaleh | PRCT | EVP, CLO, CORP. SEC. | Jan 9 '24 | Sell | $44.97 | 16,000 | $719,475.20 | 47,351 | SEC Form 4 |
Latest PROCEPT BioRobotics Corporation News
PRCT Breaking Stock News: Dive into PRCT Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
With 84% ownership of the shares, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is heavily dominated by institutional owners
MT Newswires
10 days ago
Truist Raises Price Target on PROCEPT BioRobotics to $79 From $72, Keeps Buy Rating
GlobeNewswire
11 days ago
PROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024
GuruFocus.com
a month ago
Insider Selling: EVP, CLO, Corporate Secretary Alaleh Nouri Sells Shares of PROCEPT BioRobotics ...
GlobeNewswire
a month ago
PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy
MT Newswires
a month ago
Procept BioRobotics Insider Sold Shares Worth $1,777,499, According to a Recent SEC Filing
GlobeNewswire
2 months ago
PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024
Investor's Business Daily
2 months ago
Intuitive Surgical, IBD Stock Of The Day, Feels Its Way Toward Buy Point
Compare PRCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRCT PROCEPT BioRobotics Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.